Analyzing BioRestorative Therapies (OTCMKTS:BRTX) and Viva Biotech (OTCMKTS:VBIZF)

Viva Biotech (OTCMKTS:VBIZF) and BioRestorative Therapies (OTCMKTS:BRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Viva Biotech and BioRestorative Therapies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viva Biotech	0	0	0	0	N/A
BioRestorative Therapies	0	0	1	0	3.00

BioRestorative Therapies has a consensus price target of $15.00, indicating a potential upside of 719.67%. Given BioRestorative Therapies’ higher possible upside, analysts clearly believe BioRestorative Therapies is more favorable than Viva Biotech.

Profitability

This table compares Viva Biotech and BioRestorative Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viva Biotech	N/A	N/A	N/A
BioRestorative Therapies	-13,728.83%	-120.47%	-114.48%

Valuation & Earnings

This table compares Viva Biotech and BioRestorative Therapies’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viva Biotech	N/A	N/A	N/A	N/A	N/A
BioRestorative Therapies	$149,500.00	82.87	-$18.50 million	($2.31)	-0.79

Viva Biotech has higher earnings, but lower revenue than BioRestorative Therapies.

Institutional and Insider Ownership

69.4% of BioRestorative Therapies shares are owned by institutional investors. 21.6% of BioRestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

BioRestorative Therapies beats Viva Biotech on 5 of the 8 factors compared between the two stocks.

About Viva Biotech

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure analysis of protein, and SPR technology; and PROTAC/molecular glue services. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. Viva Biotech Holdings was incorporated in 2008 and is headquartered in Shanghai, China.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.